Evidence map›Paper›PMID 34514343›Full record

ArticleHemaSphere2021

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.

Barbara Mantoan, Elisa Genuardi, Martina Ferrante, Irene Della Starza, Elena Ciabatti, Susanna Grassi, Lucia Anna De Novi, Marzia Cavalli, Claudia Mannu, Anna Gazzola and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 3 countries.

Barbara MantoanDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
Elisa GenuardiDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
Martina FerranteDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
Irene Della StarzaHematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy.
Elena CiabattiDivision of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy.
Susanna GrassiDivision of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy.
Lucia Anna De NoviHematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy.
Marzia CavalliHematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy.
Claudia MannuHematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy.
Anna GazzolaHematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy.
Riccardo BombenClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.
Massimo DeganClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.
Beatrice AlessandriaDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
Christiane PottSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
Marie-Hélène Delfau-LarueLaboratoire d'immunologie biologique, hôpital Henri-Mondor, Créteil Cedex, France.
Ramon García-SanzDivision of Hematology, Servicio de Hematología, Hospital Universitario de Salamanca, Spain.
Claudio AgostinelliHematopathology section, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Italy.
Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano, Italy.
Sara GalimbertiDivision of Hematology, Department of Clinical and Experimental Medicine, Santa Chiara Hospital, Pisa, Italy.
Ilaria Del GiudiceHematology, Department of Translational and Precision Medicine, Sapienza University of Roma, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
Marco LadettoDivision of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
Simone FerreroDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
Daniela DrandiDepartment of Molecular Biotechnologies and health sciences, Hematology Division, University of Torino, Italy.
University of Turin · ITCentro di Riferimento Oncologico · ITOspedale Santa Chiara · ITSapienza University of Rome · ITUniversity of Bologna · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITComplejo Hospitalario de Salamanca · ESFondazione Gimema Onlus · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34514343
PMCPMC8423385
OpenAlexW3196623583

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.